Skip to content

Effect of “Equmelis” on depression

Evaluation of the efficacy of “Equmelis” in patients with depression disorder

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200420047143N1
Enrollment
80
Registered
2020-05-08
Start date
2020-06-21
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Mood disorder due to known physiological condition with depressive features

Interventions

Intervention 1: Intervention group: use 5 cc “Equmelis” three times a day for 6 weeks. Intervention 2: Control group: use 5 cc placebo three times a day for 6 weeks.

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 55 Patients who sign informed consent and cooperate during the study Patients who their diseases are confirmed by psychiatrist and get at least score 18 on Hamilton scale

Exclusion criteria

Exclusion criteria: Patients with history of cognitive impairment in the last year Patients with history of bipolar disorder, schizophrenia, and schizotypal disorder Get a score of more than 2 on the Hamilton scale suicide question Pregnant women and women who do not use contraceptives.

Design outcomes

Primary

MeasureTime frame
Depression score in Hamilton scale. Timepoint: At the beginning of the study and 6 weeks after start the intervention. Method of measurement: Hamilton scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNesa Behrozi

Kermanshah University of Medical Sciences

nesab1996@gmail.com+98 35 24402

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026